Real-world evidence for using urine osmolality as a practical tool in tolvaptan dose optimization in patients with ADPKD.

INTRODUCTION: The aim of this prospective single-center study was to evaluate the role of morning urine and 24-hour urine osmolality as biomarkers for guiding individualized dosing of tolvaptan in adults with rapidly progressive autosomal dominant po…

Preview only. Read the full abstract at the source